Clinical Trial Update: CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells [Phase 1]

View source ↗

Summary

Phase 1 safety study evaluating intrahepatic infusions of anti-CEA designer T cells in patients with liver metastases has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Metastases

Drugs mentioned

• Anti-CEA designer T cells (CAR-T cells targeting CEA)

Snippet

Sponsor: Roger Williams Medical Center | Conditions: Liver Metastases | Phase 1 | Status: COMPLETED